RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
91 hedge funds and large institutions have $199M invested in RAPT Therapeutics in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 32 closing their positions.
233% more capital invested
Capital invested by funds: $59.9M → $199M (+$140M)
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
63% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 19
39% more call options, than puts
Call options by funds: $507K | Put options by funds: $365K
34.7% more ownership
Funds ownership: 10.67% → 45.37% (+35%)
9% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 32
3% less funds holding
Funds holding: 94 → 91 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MVM
Medicxi Ventures Management
St. Helier,
Jersey
|
+$35.5M |
| 2 |
O
OrbiMed
New York
|
+$20.9M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$20.9M |
| 4 |
RI
RTW Investments
New York
|
+$18.7M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
-$2.15M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$1.83M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
-$1.09M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.06M |
| 5 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
-$1.03M |
RAPT Hedge Fund Activity: Q4 2024 in Review
91 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q4 2024, worth a combined $199M — up 233% from $59.9M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of RAPT and 29 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 31 added.
The largest buyer was Medicxi Ventures Management, opening a new position worth an estimated $35.5M. The largest seller was Column Group, cutting an estimated $2.15M.
- 91 institutional investors held RAPT Therapeutics (RAPT) as of Q4 2024, down from 94 in Q3 2024.
- Funds reported $199M of RAPT Therapeutics stock for Q4 2024, up 233% quarter-over-quarter.
- 29 funds opened new RAPT Therapeutics positions in Q4 2024 and 32 closed out, a net change of -3 holders.
- The largest RAPT Therapeutics buyer in Q4 2024 was Medicxi Ventures Management, an estimated $35.5M added.
- The largest RAPT Therapeutics seller in Q4 2024 was Column Group, an estimated $2.15M sold.
Based on aggregated 13F filings for Q4 2024.